Sanofi (EPA:SAN) PT Set at €79.00 by Goldman Sachs Group

Goldman Sachs Group set a €79.00 ($91.86) price objective on Sanofi (EPA:SAN) in a research note published on Wednesday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Several other research firms have also recently commented on SAN. Deutsche Bank reaffirmed a buy rating and issued a $80.00 price objective on shares of Bayerische Motoren Werke in a research report on Monday, July 8th. JPMorgan Chase & Co. raised shares of ROYAL MAIL PLC/ADR from an underweight rating to a neutral rating in a research report on Monday, June 3rd. HSBC reiterated a buy rating and issued a price target on shares of Deutsche Telekom in a research note on Tuesday, June 11th. UBS Group reiterated a hold rating and issued a $7.80 price target on shares of Deutsche Bank in a research note on Friday, April 26th. Finally, Jefferies Financial Group reiterated a buy rating on shares of Linde in a research note on Friday, June 21st. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of €85.47 ($99.38).

SAN opened at €74.57 ($86.71) on Wednesday. Sanofi has a 12 month low of €63.09 ($73.36) and a 12 month high of €92.97 ($108.10). The company has a fifty day moving average of €75.97.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Key terms to understand channel trading

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.